A new study by researchers from Emory University’s Rollins School of Public Health and Vanderbilt University Medical Center found parental support for adolescent medical consent varied significantly depending on how the question… read more.
Pfizer Inc will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 30… read more.
Amgen announced that the global Phase III DeLLphi-304 clinical trial evaluating Imdelltra (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or… read more.
At any given time, about 100,000 people in the U.S. are waiting to become kidney transplant recipients. Roughly one-fifth of those get a new kidney each year, but… read more.
A new study by investigators from Mass General Brigham showed that teens and young adults who took varenicline—an FDA-approved, twice-daily smoking cessation pill for adults—are more than three times as… read more.
Incyte announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago…. read more.
Idorsia announced that the FDA after having released Tryvio (aprocitentan) from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on March 17, 2025), has now approved the… read more.
Background and Aims Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs specifically designed to treat liver fibrosis…. read more.
Background and objectives Oral contraceptive pills (OCPs) are commonly used for contraception, but their long-term effects on oxidative stress, lipid profiles, and liver function remain unclear. This study… read more.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, announced that the full results from the… read more.
Valneva SE announced that the Brazilian Health Regulatory Agency (ANVISA) approved Ixchiq vacccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of… read more.
A new study has found that over 1 in 5 boys and men in Canada and the United States may meet the diagnostic criteria for an eating disorder,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
